BTK Inhibitors in B-Cell Lymphomas

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.

Shuo Ma, MD, PhD, highlights ongoing ​research with BTK inhibitor​s in B​-cell malignancies. 

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.

Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.

Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.

Constantine S. Tam, MD, MBBS, discusses the 3 FDA approved BTK inhibitors in hematologic malignancies: ibrutinib, acalabrutinib, and zanubrutinib.

Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.

Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.

Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.

Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.